|
|
Volumn 3, Issue 2, 2002, Pages 103-105
|
|
Improvement in disease-free survival with doxorubicin/docetaxel/cyclophosphamide (TAC) versus 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) as adjuvant therapy for node-positive breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CIPROFLOXACIN;
CYCLOPHOSPHAMIDE;
DEXAMETHASONE;
DOCETAXEL;
DOXORUBICIN;
FLUOROURACIL;
HORMONE RECEPTOR;
TAMOXIFEN;
ADULT;
AGED;
AMENORRHEA;
ANEMIA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
ASTHENIA;
BREAST CANCER;
BREAST SURGERY;
CANCER MORTALITY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG RESPONSE;
FEBRILE NEUTROPENIA;
FEMALE;
FOLLOW UP;
GASTROINTESTINAL SYMPTOM;
HUMAN;
INFECTION;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
ONCOGENE NEU;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
STOMATITIS;
|
|
EID: 0036347859
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.1016/S1526-8209(11)70170-7 Document Type: Article |
|
Times cited : (1)
|
|
References (7)
|
